EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. today announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of its novel first-in-class kinase activator, MLR-1023, for the treatment of Type II diabetes. MLR-1023 was discovered and developed internally using Melior’s indications discovery platform, theraTRACE.
